(Source: Enanta Pharmaceuticals Inc) Sustained virologic response 12 weeks post-treatment (SVR12) of 91 percent was achieved in Japanese patients with genotype 1b (GT1b) hepatitis C virus (HCV) infection and with compensated cirrhosis1 AbbVie's treatment for Japanese patients with GT1b HCV infection consists of a 12-week, two direct-acting antiviral, fixed-dosed combination of paritaprevir/ritonavir/ombitasvir, dosed once daily Regimen contains Enanta's lead protease inhibitor, paritaprevir WATERTOWN, Mass.--(BUSINESS WIRE)--May 26, 2015-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral...
↧